报价延迟最少15分钟:2025/08/25 04:51 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.09
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.44/-1.71
|
|
企业价值
116.30M
|
| 资产负债 |
|
每股账面净值
-0.99
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
24.38M
|
|
每股收益
1.14
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/25 04:51 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patientsreceiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection. |
